Histogenics (NASDAQ:HSGX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Wednesday.
According to Zacks, “Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. “
A number of other analysts also recently commented on HSGX. HC Wainwright reiterated a “buy” rating and issued a $3.50 target price on shares of Histogenics in a report on Thursday, November 2nd. Canaccord Genuity reiterated a “buy” rating and issued a $4.00 target price on shares of Histogenics in a report on Thursday, December 21st.
Histogenics (NASDAQ:HSGX) last released its earnings results on Thursday, November 9th. The biotechnology company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.07. sell-side analysts predict that Histogenics will post -1.12 earnings per share for the current fiscal year.
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.